Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany
Open Access
- 23 July 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 9, 569
Abstract
Objective: To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely drug refractory cohort of patients with epileptic encephalopathies (EE). Method: A multicenter, retrospective cohort study recruiting all patients treated with EE who began treatment with BRV in an enrolling epilepsy center between 2016 and 2017. Results: Forty-four patients (27 male [61%], mean age 29 years, range 6 to 62) were treated with BRV. The retention rate was 65% at 3 months, 52% at 6 months and 41% at 12 months. A mean retention time of 5 months resulted in a cumulative exposure to BRV of 310 months. Three patients were seizure free during the baseline. At 3 months, 20 (45%, 20/44 as per intention-to-treat analysis considering all patients that started BRV including three who were seizure free during baseline) were either seizure free (n = 4; 9%, three of them already seizure-free at baseline) or reported at least 25% (n = 4; 9%) or 50% (n = 12; 27%) reduction in seizures. An increase in seizure frequency was reported in two (5%) patients, while there was no change in the seizure frequency of the other patients. A 50% long-term responder rate was apparent in 19 patients (43%), with two (5%) free from seizures for more than six months and in nine patients (20%, with one [2 %] free from seizures) for more than 12 months. Treatment-emergent adverse events were predominantly of psychobehavioural nature and were observed in 16%. Significance: In this retrospective analysis the rate of patients with a 50% seizure reduction under BRV proofed to be similar to those seen in regulatory trials for focal epilepsies. BRV appears to be safe and relatively well tolerated in EE and might be considered in patients with psychobehavioral adverse events while on levetiracetam.Keywords
This publication has 54 references indexed in Scilit:
- Lessons from the RAMPART study—and which is the best route of administration of benzodiazepines in status epilepticusEpilepsia, 2013
- Epileptic Encephalopathies: An OverviewEpilepsy Research and Treatment, 2012
- Epileptic Encephalopathies in Adults and ChildhoodEpilepsy Research and Treatment, 2012
- Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2ABritish Journal of Pharmacology, 2008
- Clinical efficacy of zonisamide in Lennox–Gastaut syndrome: Korean multicentric experienceBrain and Development, 2008
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007
- The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- Topiramate in Lennox–Gastaut Syndrome: Open‐Label Treatment of Patients Completing a Randomized Controlled TrialEpilepsia, 2000
- Felbamate in the Treatment of Lennox‐Gastaut SyndromeEpilepsia, 1994
- Felbamate in the Treatment of Lennox‐Gastaut Syndrome: Results of a 12‐Month Open‐Label Study Following a Randomized Clinical TrialEpilepsia, 1993